Showing 40,021 - 40,040 results of 102,692 for search '(( i et decrease ) OR ( 5 ((point decrease) OR (((a decrease) OR (mean decrease)))) ))', query time: 1.85s Refine Results
  1. 40021

    Thermodynamic parameters. by Jianqing Jia (21001506)

    Published 2025
    “…Consequently, tunnel reliability decreases. Specifically, with temperature increases of 2.6 °C and 4 °C, tunnel reliability decreases by approximately 4.5% and 6.3%, respectively, when considering insulation layer deterioration.…”
  2. 40022

    Alteration of Pituitary Tumor Transforming Gene-1 Regulates Trophoblast Invasion via the Integrin/Rho-Family Signaling Pathway by Seung Mook Lim (2267395)

    Published 2016
    “…Furthermore, knockdown of PTTG1 increased expression of integrin alpha 4 (ITGA4), ITGA5, and integrin beta 1 (ITGB1); otherwise, RhoA expression was significantly decreased (<i>p <</i> 0.05). …”
  3. 40023

    Table_1_Dysregulation of Principal Circulating miRNAs in Non-human Primates Following Ischemic Stroke.XLSX by Jian Chen (15340)

    Published 2021
    “…For example, mml-miR-191-5p, miR-421, miR-409-5p, and let-7g-5p were found to be significantly overexpressed, whereas mml-miR-128a-5p_R − 2, miR-431_R − 1, and let-7g-3p_1ss22CT were significantly downregulated. …”
  4. 40024

    Trends in use of prescription stimulants in the United States and Territories, 2006 to 2016 by Brian J. Piper (412361)

    Published 2018
    “…</p><p>Results</p><p>Amphetamine use increased 2.5 fold from 2006 to 2016 (7.9 to 20.0 tons). Methylphenidate use, at 16.5 tons in 2006, peaked in 2012 (19.4 tons) and subsequently showed a modest decline (18.6 tons in 2016). …”
  5. 40025
  6. 40026
  7. 40027
  8. 40028
  9. 40029

    Image_2_A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors.tif by James J. Harding (12415627)

    Published 2022
    “…Adult patients with treatment-refractory solid tumors received PF-06671008 (1.5–400 ng/kg) as a weekly intravenous (IV) infusion on a 21-day/3-week cycle. …”
  10. 40030

    Image_1_A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors.tif by James J. Harding (12415627)

    Published 2022
    “…Adult patients with treatment-refractory solid tumors received PF-06671008 (1.5–400 ng/kg) as a weekly intravenous (IV) infusion on a 21-day/3-week cycle. …”
  11. 40031

    Supplementary Material for: Mortality and Cardiovascular Morbidity Associated with Haemoglobin Levels: A Pooled Analysis of Randomised Controlled Trials by Locatelli F. (3698788)

    Published 2017
    “…<b><i>Results:</i></b> Average Hb <10 g/dl, decrease from stable baseline Hb >1 g/dl, last Hb <10 g/dl, Hb decline >1.5 g/dl/4 weeks and increased Hb variability were associated with a higher risk of the composite end point and all-cause mortality. …”
  12. 40032
  13. 40033
  14. 40034
  15. 40035
  16. 40036
  17. 40037
  18. 40038
  19. 40039
  20. 40040